Literature DB >> 32404255

Vascular and inflammatory effects of estrogen and anti-androgen therapy in the testis and epididymis of male to female transgender adults.

Cristina Peña Barreno1, Pilar Gonzalez-Peramato2, Manuel Nistal3.   

Abstract

The volume of ubiquitous chemicals with estrogenic properties is on the rise and some reports relate the increase in hormonal diseases to these compounds. A morphological and immunohistochemical analysis has been performed on 42 bilateral orchiectomy specimens from adult individuals who underwent gender reassignment surgery after receiving crossed-sex hormone therapy to give insight into vascular, inflammatory and epididymal changes following long-term treatment with estrogens and antiandrogens and raise awareness of the consequences of hormone therapy. The present study confirms previously reported findings in testicular parenchyma and epididymis, such as identification of three histological patterns according to lesion severity and cell dedifferentiation, and reports for the first time vascular and inflammatory lesions (atherosclerosis and vasculitis), both on testicle and epididymis. Cross-sex hormone therapy should be provided in specialized units in order to systematize treatments and ensure adequate follow-up.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiandrogen; Atherosclerosis; Epididymis; Estrogen; Gender identity reassignment; Testicular dysgenesis syndrome; Testis; Vasculitis

Mesh:

Substances:

Year:  2020        PMID: 32404255     DOI: 10.1016/j.reprotox.2020.05.001

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  1 in total

1.  Clinicopathologic features and proposed grossing protocol of orchiectomy specimens performed for gender affirmation surgery.

Authors:  Kristine M Cornejo; Esther Oliva; Rory Crotty; Peter M Sadow; Kyle Devins; Anton Wintner; Chin-Lee Wu
Journal:  Hum Pathol       Date:  2022-06-02       Impact factor: 3.526

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.